Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 1
1991 1
1994 1
1995 2
1996 3
1997 9
1998 12
1999 25
2000 45
2001 24
2002 34
2003 33
2004 33
2005 30
2006 32
2007 36
2008 47
2009 45
2010 48
2011 39
2012 39
2013 46
2014 41
2015 37
2016 28
2017 27
2018 28
2019 28
2020 25
2021 16
2022 15
2023 24
2024 17

Text availability

Article attribute

Article type

Publication date

Search Results

806 results

Results by year

Filters applied: . Clear all
Page 1
Phase 1/2a clinical trial in ALS with ropinirole, a drug candidate identified by iPSC drug discovery.
Morimoto S, Takahashi S, Ito D, Daté Y, Okada K, Kato C, Nakamura S, Ozawa F, Chyi CM, Nishiyama A, Suzuki N, Fujimori K, Kondo T, Takao M, Hirai M, Kabe Y, Suematsu M, Jinzaki M, Aoki M, Fujiki Y, Sato Y, Suzuki N, Nakahara J; Pooled Resource Open-Access ALS Clinical Trials Consortium; Okano H. Morimoto S, et al. Cell Stem Cell. 2023 Jun 1;30(6):766-780.e9. doi: 10.1016/j.stem.2023.04.017. Cell Stem Cell. 2023. PMID: 37267913 Free article. Clinical Trial.
iPSC-based drug discovery led to a phase 1/2a trial of ropinirole in ALS. 20 participants with sporadic ALS received ropinirole or placebo for 24 weeks in the double-blind period to evaluate safety, tolerability, and therapeutic effects. ...However, in the op …
iPSC-based drug discovery led to a phase 1/2a trial of ropinirole in ALS. 20 participants with sporadic ALS received ropinirole …
Comparison of pramipexole versus ropinirole in the treatment of Parkinson's disease.
Gencler OS, Oztekin N, Oztekin MF. Gencler OS, et al. Ideggyogy Sz. 2022 Jan 30;75(1-02):39-49. doi: 10.18071/isz.75.0039. Ideggyogy Sz. 2022. PMID: 35112520 Free article. Clinical Trial. English.
Dopamine agonist monotherapy and levodopa add-on therapy patients were randomized into two groups to receive either pramipexole or ropinirole. The maximum daily dosages of pramipexole and ropinirole were 4.5 mg and 24 mg respectively. ...CONCLUSION: This study suppo …
Dopamine agonist monotherapy and levodopa add-on therapy patients were randomized into two groups to receive either pramipexole or ropini …
Ropinirole, a non-ergoline dopamine agonist.
Jost WH, Angersbach D. Jost WH, et al. CNS Drug Rev. 2005 Autumn;11(3):253-72. doi: 10.1111/j.1527-3458.2005.tb00046.x. CNS Drug Rev. 2005. PMID: 16389293 Free PMC article. Review.
This review article provides a closer look at the experimental and clinical studies with ropinirole published so far. Ropinirole is a non-ergoline dopamine agonist which has been proven to be effective in both, monotherapy and combination therapy of idiopathic Parki …
This review article provides a closer look at the experimental and clinical studies with ropinirole published so far. Ropinirole …
Ropinirole: a review of its use in the management of Parkinson's disease.
Matheson AJ, Spencer CM. Matheson AJ, et al. Drugs. 2000 Jul;60(1):115-37. doi: 10.2165/00003495-200060010-00007. Drugs. 2000. PMID: 10929932 Review.
Ropinirole is indicated as adjunct therapy to levodopa in patients with advanced Parkinson's disease. ...Ropinirole was well tolerated either as monotherapy or as an adjunct to levodopa treatment. ...
Ropinirole is indicated as adjunct therapy to levodopa in patients with advanced Parkinson's disease. ...Ropinirole was well t …
Ropinirole treatment for restless legs syndrome.
Chitnis S. Chitnis S. Expert Opin Drug Metab Toxicol. 2008 May;4(5):655-64. doi: 10.1517/17425255.4.5.655. Expert Opin Drug Metab Toxicol. 2008. PMID: 18484922 Review.
Significant improvements in RLS symptoms were observed within 2 nights of treatment. Ropinirole also produced significant benefits on objective measures of RLS motor symptoms, such as periodic leg movements; and on subjective measures of sleep, ropinirole was genera …
Significant improvements in RLS symptoms were observed within 2 nights of treatment. Ropinirole also produced significant benefits on …
Ropinirole: current status of the studies.
Jost WH. Jost WH. J Neurol. 2004 Sep;251 Suppl 6:VI/13-8. doi: 10.1007/s00415-004-1604-8. J Neurol. 2004. PMID: 15675719 Review.
Ropinirole is a modern, non-ergoline dopamine agonist which has been shown to be effective as monotherapy as well as combination therapy against idiopathic Parkinson's disease. ...A neuroprotective effect is under discussion. In addition to Parkinson's disease, ropiniro …
Ropinirole is a modern, non-ergoline dopamine agonist which has been shown to be effective as monotherapy as well as combination ther …
Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent.
Fujimori K, Ishikawa M, Otomo A, Atsuta N, Nakamura R, Akiyama T, Hadano S, Aoki M, Saya H, Sobue G, Okano H. Fujimori K, et al. Nat Med. 2018 Oct;24(10):1579-1589. doi: 10.1038/s41591-018-0140-5. Epub 2018 Aug 20. Nat Med. 2018. PMID: 30127392
We further evaluated multiple-phenotype rescue of these subclassified SALS models using agents selected from non-SOD1 FALS models, and identified ropinirole as a potential therapeutic candidate. Integration of the datasets acquired in this study permitted the visual …
We further evaluated multiple-phenotype rescue of these subclassified SALS models using agents selected from non-SOD1 FALS models, and ident …
Ropinirole: for the treatment of restless legs syndrome.
Cheer SM, Bang LM, Keating GM. Cheer SM, et al. CNS Drugs. 2004;18(11):747-54; discussion 755-6. doi: 10.2165/00023210-200418110-00004. CNS Drugs. 2004. PMID: 15330688 Review.
Ropinirole is a non-ergoline dopamine agonist that exhibits a high affinity for D(2) and D(3) receptors but little or no affinity for D(1)-like and non-dopaminergic receptors. ...Few patients receiving ropinirole withdrew from therapy because of adverse events, the …
Ropinirole is a non-ergoline dopamine agonist that exhibits a high affinity for D(2) and D(3) receptors but little or no affinity for …
Ropinirole therapy for Parkinson's disease.
Pahwa R, Lyons KE, Hauser RA. Pahwa R, et al. Expert Rev Neurother. 2004 Jul;4(4):581-8. doi: 10.1586/14737175.4.4.581. Expert Rev Neurother. 2004. PMID: 15853577 Review.
When used as monotherapy in early Parkinson's disease, ropinirole improves signs and symptoms of the disorder. When used as an adjunct to levodopa in advanced Parkinson's disease patients with motor fluctuations, ropinirole reduces off time and allows a reduction of …
When used as monotherapy in early Parkinson's disease, ropinirole improves signs and symptoms of the disorder. When used as an adjunc …
Ropinirole for levodopa-induced complications in Parkinson's disease.
Clarke CE, Deane KH. Clarke CE, et al. Cochrane Database Syst Rev. 2000;(3):CD001516. doi: 10.1002/14651858.CD001516. Cochrane Database Syst Rev. 2000. Update in: Cochrane Database Syst Rev. 2001;(1):CD001516. doi: 10.1002/14651858.CD001516. PMID: 10908503 Updated. Review.
Levodopa dose could be reduced in two studies with a significantly larger reduction on ropinirole than on placebo (WMD 136.5mg/d; 74.5, 198.6 95% CI; p =0.00002). No significant differences in the frequency of adverse event reports were noted between ropinirole and …
Levodopa dose could be reduced in two studies with a significantly larger reduction on ropinirole than on placebo (WMD 136.5mg/d; 74. …
806 results